Medicines Company gains anti-infectives in $140m Rempex buy
This article was originally published in Scrip
Executive Summary
The Medicines Company (MDCO) added a Phase III-ready drug candidate and other anti-infective programs to its pipeline via the acquisition of privately-held, San Diego-based Rempex Pharmaceuticals for $140m up front and up to $334m in milestone payments.